- Home
- GO vs ORIC Comparison
GO vs ORIC Comparison
Compare GO & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GO | ORIC |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GO | ORIC |
|---|---|---|
| Price | $11.36 | $11.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $15.50 | ★ $18.78 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,571,346,000.00 | N/A |
| Revenue This Year | $10.74 | N/A |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.22 | N/A |
| 52 Week Low | $10.21 | $3.90 |
| 52 Week High | $19.97 | $14.93 |
Technical Indicators
Market Signals| Indicator | GO | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 40.48 | 40.42 |
| Support Level | $10.82 | $10.45 |
| Resistance Level | $11.44 | $12.14 |
| Average True Range (ATR) | 0.42 | 0.77 |
| MACD | 0.23 | -0.08 |
| Stochastic Oscillator | 84.62 | 26.05 |
Price Performance
Historical ComparisonAbout GO Grocery Outlet Holding Corp.
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.